MX2021013814A - Formas cristalinas de n-(5-(5-((1r,2s)-2-fluorociclopropil)-1,2,4- oxadiazol-3-yl)-2- metilfenil)imidazo[1,2-a]piridin-3-carboxamida. - Google Patents
Formas cristalinas de n-(5-(5-((1r,2s)-2-fluorociclopropil)-1,2,4- oxadiazol-3-yl)-2- metilfenil)imidazo[1,2-a]piridin-3-carboxamida.Info
- Publication number
- MX2021013814A MX2021013814A MX2021013814A MX2021013814A MX2021013814A MX 2021013814 A MX2021013814 A MX 2021013814A MX 2021013814 A MX2021013814 A MX 2021013814A MX 2021013814 A MX2021013814 A MX 2021013814A MX 2021013814 A MX2021013814 A MX 2021013814A
- Authority
- MX
- Mexico
- Prior art keywords
- fluorocyclopropyl
- oxadiazol
- pyridine
- imidazo
- carboxamide
- Prior art date
Links
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 2
- 239000013078 crystal Substances 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000001530 fumaric acid Substances 0.000 abstract 2
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- -1 N-(5-(5-((1R,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-2-m ethylphenyl)imidazo[1,2-a]pyridine-3-carboxamide fumaric acid Chemical compound 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000016097 disease of metabolism Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 210000003630 histaminocyte Anatomy 0.000 abstract 1
- ZMBYQTGAXZOMOO-UHFFFAOYSA-N imidazo[1,2-a]pyridine-3-carboxamide Chemical compound C1=CC=CN2C(C(=O)N)=CN=C21 ZMBYQTGAXZOMOO-UHFFFAOYSA-N 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- RHNJOZCVGSBEAG-KBPBESRZSA-N n-[5-[5-[(1r,2s)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl]imidazo[1,2-a]pyridine-3-carboxamide Chemical compound C1=C(NC(=O)C=2N3C=CC=CC3=NC=2)C(C)=CC=C1C(N=1)=NOC=1[C@H]1C[C@@H]1F RHNJOZCVGSBEAG-KBPBESRZSA-N 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019086582 | 2019-05-13 | ||
| PCT/CN2020/090060 WO2020228746A1 (en) | 2019-05-13 | 2020-05-13 | Crystalline forms of n- (5- (5- ( (1r, 2s) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021013814A true MX2021013814A (es) | 2022-02-10 |
Family
ID=73289607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021013814A MX2021013814A (es) | 2019-05-13 | 2020-05-13 | Formas cristalinas de n-(5-(5-((1r,2s)-2-fluorociclopropil)-1,2,4- oxadiazol-3-yl)-2- metilfenil)imidazo[1,2-a]piridin-3-carboxamida. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220194936A1 (enExample) |
| EP (1) | EP3969453A4 (enExample) |
| JP (1) | JP2022533340A (enExample) |
| KR (1) | KR20220007650A (enExample) |
| CN (1) | CN114096538A (enExample) |
| AU (1) | AU2020274564A1 (enExample) |
| BR (1) | BR112021022685A2 (enExample) |
| CA (1) | CA3139552A1 (enExample) |
| IL (1) | IL287877A (enExample) |
| MA (1) | MA55976A (enExample) |
| MX (1) | MX2021013814A (enExample) |
| SG (1) | SG11202112281UA (enExample) |
| TW (1) | TW202108581A (enExample) |
| WO (1) | WO2020228746A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023534963A (ja) * | 2020-07-15 | 2023-08-15 | サード ハーモニック バイオ， インコーポレイテッド | 選択的ｃ－ｋｉｔキナーゼ阻害剤の結晶質形態 |
| TW202237096A (zh) * | 2020-11-19 | 2022-10-01 | 瑞士商諾華公司 | 選擇性ｃ－ｋｉｔ激酶抑制劑之醫藥組合物及其製造及使用方法 |
| TW202237097A (zh) * | 2020-11-19 | 2022-10-01 | 美商第三諧波生物公司 | 選擇性ｃ－ｋｉｔ激酶抑制劑之醫藥組合物及其製造及使用方法 |
| EP4626884A1 (en) | 2022-11-30 | 2025-10-08 | Blueprint Medicines Corporation | N-phenyl-pyrazolo[1,5-a]pyridine-3-carboxamide derivatives as wild type c-kit kinase inhibitors for the treatment of urticaria |
| CN122580315A (zh) * | 2024-01-04 | 2026-08-14 | 上海翰森生物医药科技有限公司 | 多环类衍生物抑制剂、其制备方法和应用 |
| WO2025256609A1 (en) * | 2024-06-13 | 2025-12-18 | Third Harmonic Bio, Inc. | Crystalline forms of a selective c-kit kinase inhibitor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2845785A1 (en) * | 2011-09-01 | 2013-03-07 | Irm Llc | Compounds and compositions as c-kit kinase inhibitors |
| CN103930424A (zh) * | 2011-09-01 | 2014-07-16 | Irm责任有限公司 | 作为c-Kit激酶抑制剂的化合物和组合物 |
| US8569283B2 (en) * | 2011-09-01 | 2013-10-29 | Valentina Molteni | Compounds and compositions as c-Kit kinase inhibitors |
| US9199981B2 (en) * | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
-
2020
- 2020-05-13 TW TW109115939A patent/TW202108581A/zh unknown
- 2020-05-13 EP EP20805948.5A patent/EP3969453A4/en not_active Withdrawn
- 2020-05-13 SG SG11202112281UA patent/SG11202112281UA/en unknown
- 2020-05-13 CN CN202080050607.4A patent/CN114096538A/zh active Pending
- 2020-05-13 AU AU2020274564A patent/AU2020274564A1/en not_active Abandoned
- 2020-05-13 BR BR112021022685A patent/BR112021022685A2/pt not_active IP Right Cessation
- 2020-05-13 KR KR1020217040220A patent/KR20220007650A/ko not_active Ceased
- 2020-05-13 MX MX2021013814A patent/MX2021013814A/es unknown
- 2020-05-13 JP JP2021567913A patent/JP2022533340A/ja active Pending
- 2020-05-13 CA CA3139552A patent/CA3139552A1/en active Pending
- 2020-05-13 MA MA055976A patent/MA55976A/fr unknown
- 2020-05-13 WO PCT/CN2020/090060 patent/WO2020228746A1/en not_active Ceased
- 2020-05-13 US US17/595,260 patent/US20220194936A1/en not_active Abandoned
-
2021
- 2021-11-07 IL IL287877A patent/IL287877A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202112281UA (en) | 2021-12-30 |
| CA3139552A1 (en) | 2020-11-19 |
| AU2020274564A1 (en) | 2021-12-09 |
| CN114096538A (zh) | 2022-02-25 |
| TW202108581A (zh) | 2021-03-01 |
| BR112021022685A2 (pt) | 2022-03-29 |
| US20220194936A1 (en) | 2022-06-23 |
| WO2020228746A1 (en) | 2020-11-19 |
| EP3969453A4 (en) | 2023-01-18 |
| MA55976A (fr) | 2022-03-23 |
| IL287877A (en) | 2022-01-01 |
| KR20220007650A (ko) | 2022-01-18 |
| JP2022533340A (ja) | 2022-07-22 |
| EP3969453A1 (en) | 2022-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021022685A2 (pt) | Formas cristalinas de n-(5-(5-((1r,2s)-2-fluorociclopropil)-1,2,4-oxadiazol-3-il)-2-metilfenil)imidazo[1,2-a]piridina-3-carboxamida | |
| WO2009033762A3 (en) | Use of endothelin-3 as a therapeutic agent | |
| WO2009033711A3 (en) | Use of glp-1 as a therapeutic agent | |
| WO2009033783A3 (en) | Use of carbetocin to treat of eg aids or idiopathic pulmonary fibrosis | |
| WO2009043505A3 (en) | Use of beta-melanotropin as a therapeutic agent, eg for the treatment of aids or alzheimer | |
| WO2009033681A3 (en) | Cyclo-argd as a therapeutic agent | |
| WO2009033793A3 (en) | Pentagastrin as a therapeutic agent | |
| WO2009033800A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009033789A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009033739A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009046845A3 (en) | Use of a lactoferrin partial peptide peptide as a therapeutic agent | |
| WO2009040048A3 (en) | Use of the c-reactive peptide as a therapeutic agent | |
| WO2009033778A3 (en) | Mage-3 antigen and others for use as a therapeutic agent | |
| WO2009033723A3 (en) | Use of aip2 as a therapeutic agent | |
| WO2009040072A3 (en) | Use of angiotensin i as a therapeutic agent in the treatment of eg aids or tuberculosis | |
| WO2009039991A3 (en) | Use of aviptadil as a therapeutic agent | |
| WO2009046864A3 (en) | Use of the human pancreatic polypeptide as a therapeutic agent | |
| WO2009040023A3 (en) | Use of galnon as a therapeutic agent | |
| WO2009033779A3 (en) | Nociceptin for use as a therapeutic agent |